Man versus mosquito: we're trying to win the battle.

Scientific discoveries with clear economic implications don’t come along every day. We’re hoping that our malaria vaccine candidate, RTS,S, will be that kind of discovery. And a CNBC report on the vaccine candidate that aired today today examines the “revolution” such a vaccine could bring.

The Centers for Disease Control and Prevention estimate that the direct costs of malaria (for example, illness, treatment, premature death) could be at least $12 billion per year. The cost in lost economic growth is many times more.

CDC reports that 3.4 billion people -- half the world’s population -- live in areas at risk of malaria transmission in 106 countries and territories. Our RTS,S vaccine is aimed at helping some of those most at risk: the very young children in sub-Saharan Africa.

We are determined to help stop this disease, and along with our partner organizations we are optimistic this can be achieved. Our vaccine initiative is an important part of our malaria strategy but other approaches -- community investment activities through our African Malaria Partnership and preferential pricing for anti-malarials in the least developed countries and sub-Saharan Africa – also are important.

Watch how we hope to make a difference in the lives of many vulnerable people.